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Abstract
Background:  External medication that is absorbed percutaneously may be used to reduce
inflammation and relieve pain from acute injuries such as ankle sprains and bruises. The plaster
method of percutaneous absorption for non-steroidal anti-inflammatory drugs (NSAIDs) was
established in Japan in 1988. However, due to the possibility of a placebo effect, the efficacy of this
method remains unclear. This experimental study was conducted to control for the placebo effect
and to study the efficacy of the plaster method in relieving pain by using a rat model of inflammation.
Methods: Male Wistar-Imamichi rats were used. A yeast suspension was injected into the right
hind paw to induce inflammation. A sheet (2.0 × 1.75 cm) containing the drug was adhered to the
inflamed paw. Five treatment groups were used, and each sheet contained a single drug: loxoprofen
sodium (loxoprofen-Na) (2.5 mg); felbinac (1.75 mg); indomethacin (1.75 mg); ketoprofen (0.75
mg); or base only (control, 0 mg). Mechanical pain threshold, expression of c-Fos in the dorsal horn,
and amount of prostaglandin (PG) E2 in the inflamed paw were evaluated.
Results:  Pain threshold increased after treatment, and was significantly increased in the
loxoprofen-Na group compared with the control group (p  < 0.05). Amounts of PGE2 were
significantly decreased in the loxoprofen-Na and indomethacin groups compared with the control
group (p < 0.05). Expression of c-Fos was significantly decreased in the loxoprofen-Na group
compared with the control group (p < 0.05).
Conclusion: Percutaneously absorbed NSAIDs have an analgesic effect, inhibit expression of c-Fos
in the dorsal horn, and reduce PGE2 in inflamed tissue, indicating the efficacy of this method of
administration for acute inflammation and localized pain.
Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly used in clinical situations worldwide to reduce
inflammation and pain. These agents are administered
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orally, intravenously, intrarectally and percutaneously.
Topical applications for percutaneous absorption com-
prise several forms, such as ointments, lotions, aerosols,
liniments, cataplasms and plasters, and pressure-sensitive
adhesives. A plaster method of percutaneous absorption
for NSAIDs was developed in Japan in 1988. This applica-
tion is used to reduce inflammation and to relieve pain
from acute injuries such as sprains and bruises. This dif-
fers from patch-type drugs for systemic administration.
However, in clinical situations, external medicines are not
typically used as a main conservative treatment because
the efficacy of this method in humans remains unclear
due to the possibility of a placebo effect. Since the effects
of plaster treatment can be separated from the placebo
effect, an experimental study was needed to evaluate the
efficacy of this method. Few preclinical experiments have
investigated the analgesic effects of percutaneous absorp-
tion with these types of drugs.
NSAIDs inhibit the biosynthesis of prostaglandins (PGs),
and PGE2 is one of the inflammatory mediators associated
with inducing peripheral hyperalgesia [1]. PGE2 levels can
be used to determine the effect of the medication as an
index of inflammation. In addition, the c-Fos  gene is
expressed following noxious input, and level of expres-
sion offers a marker of signals to sensory cells in the spinal
cord [2-4]. The purpose of this study was to investigate the
effects of plaster treatment on mechanical hyperalgesia,
expression of c-Fos in the spinal cord, and the amount of
PGE2 in a rat model of inflammation.
Methods
A total of 90 male Wistar-Imamichi rats (4–5 weeks old;
Imamichi Institute of Animal Reproduction, Japan) were
used in this study. Animals were housed in plastic cages at
room temperature with a 12:12 light:dark cycle and ad
libitum  access to food and water. All experiments were
approved by the Animal Studies Committee at Fukushima
Medical University.
Acute inflammatory model
Animals were anesthetized using 99% diethyl ether
(Wako Pure Chemical Industries, Osaka, Japan). A sus-
pension of 10% or 20% brewer's yeast (Sigma-Aldrich,
MO, USA) at 0.1 ml/hind paw was injected intradermally
into the right hind paw. According to Randall and Selitto
[5], 20% brewer's yeast induces inflammation. Pain
threshold is reduced at 1 h and is further decreased at 2
and 4 h. A return to baseline is seen by 48 h after induc-
tion of inflammation. However, efficacy of treatment with
use of 20% yeast was only found according to PGE2 level,
and not pain threshold or c-Fos expression (data not
shown). As the degree of inflammation using 20% yeast
thus appeared too strong to evaluate pain threshold and
c-Fos expression by the percutaneous drug delivery sys-
tem, 10% yeast was used. To prevent ingestion of the drug
sheet, an Elizabethan collar comprising a plastic sheet was
applied around the neck of each rat (Fig. 1).
Treatment groups
Animals were divided into 5 groups and treated with dif-
ferent percutaneously absorbed drugs. All drugs were clin-
ically applied in the form of a patch sheet (10.0 × 14.0
cm) to the affected area. Drug dose per sheet was 100 mg
loxoprofen sodium (loxoprofen-Na), 70 mg felbinac, 70
mg indomethacin or 30 mg ketoprofen. Since the density
of each drug imbedded in the sheet differed, the applied
dose was controlled by standardizing sheet size in this
study at 2.0 cm × 1.75 cm, based on the relative difference
between human and rat body sizes. The sheet for rat treat-
ment contained 2.5 mg loxoprofen-Na, 1.75 mg felbinac,
1.75 mg indomethacin or 0.75 mg ketoprofen. Control
rats received an application of a base sheet, representing a
sheet without NSAIDs (control; 0 mg). This base sheet
contained several substances to improve drug absorption,
control drug release and minimize skin irritation. To
exclude the influence of such substances, treatment
groups were compared to the control group treated with
the base sheet alone. A sheet of each drug was applied to
the paw for treatment and covered by a net to prevent the
sheet from coming off (Fig. 2).
Measurement of pain threshold
Pain threshold was measured using 30 rats (n = 6 per
group). Treatments were started 4.5 h after 10% yeast
injection. The pain threshold began to decrease at 1 h and
decreased further by 2 and 4 h, returning to baseline by 48
h after induction of inflammation [5]. In addition, swell-
ing of the paw is reportedly maximized at 2–5 h after
inflammation is induced and is maintained for more than
5 h [6]. As a result, to investigate the efficacy of NSAID
sheets, treatments were started on the basis of active
inflammation according to the clinical situation, and pain
Acute inflammatory model and plastic Elizabethan collar for  the rat neck Figure 1
Acute inflammatory model and plastic Elizabethan 
collar for the rat neck. a) A suspension of yeast was 
injected intradermally into the right paw (*). b) A plastic Eliz-
abethan collar was fixed around the neck of each rat to pre-
vent ingestion of the drug sheet.
*
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thresholds were measured. Experiments were performed
according to the method of Randall and Selitto [5], with
the same modifications used by Winter and Flataker [6].
Just before treatment, pain thresholds were measured on
bilateral paws. Pain thresholds were measured using the
Analgesy-Meter (Ugo Basile, Comerio, Italy), which is
able to gradually apply pressure to the paw, and the
degree of pressure is shown on a graduated scale. Strug-
gling or vocalization was considered as a positive pain
response. Two sheets were adhered to the dorsal and
plantar sides of paw. Pain thresholds were measured 3 h
after treatment to compare groups. Measurement of pain
thresholds was performed once on each rat at each time
point. Data are shown as mean ± standard deviation. Sta-
tistical analysis was performed using the Bonferroni/
Dunn test. Values of p < 0.05 were considered statistically
significant.
Amount of PGE2 in inflamed tissue
Levels of PGE2 were assayed using 35 rats (n = 6 in each
treatment group; n = 5 for treatment-naïve rats). Induced
inflammation was not administered to naïve rats, and
they were not given any treatment. Paws were treated with
treated or control sheets immediately after injection of
20% yeast suspension. One sheet was adhered to the dor-
sal side of the paw.
The amount of PGE2 was measured 0.5 h after treatment.
Since PGE2 induces peripheral hyperalgesia [1], produc-
tion of PGE2 might start shortly after injection. To deter-
mine whether drugs inhibit PGE2 production, drugs sheets
were adhered immediately after injection. In addition, if
drugs inhibit production of PGE2, expression of c-Fos
would be related to this response, so we chose the same
period for these measurements. Rats were euthanized
using 99% diethyl ether, then inflamed paws were iso-
lated 0.5 h after treatment, immediately frozen with liq-
uid nitrogen and stored at -80°C. Whole paws were
crushed in a Cryo-press (Microtec, Tokyo, Japan), then
homogenized with a Polytron PT-3100 homogenizer
(Kinematica, NJ, USA) in ice-cold phosphate-buffered
saline (PBS) supplemented with 10 mM EDTA and 100
μM indomethacin (Sigma-Aldrich). The homogenate was
centrifuged, and the supernatant fraction was stored at -
20°C until the PGE2 assay. PGE2 content was assayed
using a PGE2 EIA kit (Cayman Chemical Company, MI,
USA). All raw data are shown in the graph. Statistical anal-
yses were performed using the Bonferroni/Dunn test. Val-
ues of p < 0.05 were considered statistically significant.
Expression of c-Fos in the dorsal horn
Histological findings were analyzed using 25 rats (n = 5
per group). Paws were treated with treated or control
sheets immediately after 10% yeast suspension injection.
Two sheets were adhered on the dorsal and plantar sides
of the paw. Perfusion was conducted 0.5 h after treatment.
Expression of c-Fos is known to peak at 30 min in the
superficial laminae of the dorsal horn after nociceptive
stimulation [7]. We therefore investigated expression of c-
Fos 30 min after stimulation and treatment. After per-
fusion with 200 ml of 4% paraformaldehyde-0.1 M PBS,
Sheet application Figure 2
Sheet application. a) Sheet size was 2.0 cm × 1.75 cm. b) 
The sheet was applied to the paw. c) The foot was covered 
by a net to prevent the sheet peeling off.
a
b
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the spinal cord at the L5 level was removed. This section
of spinal cord was then immersed in 4% paraformalde-
hyde-0.1 M PBS solution for 1 h, in a 10% sucrose-PBS
solution for 24 h, and in a 20% sucrose-PBS solution for
24 h. A 40-μm frozen section was made from the spinal
cord using a microtome. Sections were collected as float-
ing sections in 0.1 M PBS, and these were immersed in 0.1
M PBS including 0.2% Triton X for 3 days. Sections were
immersed in 1% blocking serum for 30–60 min, then
reacted with anti-c-Fos antibody (1:3000; Santa Cruz Bio-
technology, CA, USA) at a temperature of 4°C for 48 h.
Sections were then reacted using the avidin-biotin com-
plex method (Vector Laboratories, CA, USA) for 30 min,
followed by washing in biotinylated IgG antibody (Vector
Laboratories) for 30 min. Afterwards, sections were
stained using a 3,3'-diaminobenzidine, 0.0045% hydro-
gen peroxide solution and placed on a glass slide to keep
dry.
A microscope connected to a computer was used at 400×
magnification. The c-Fos-immunoreactive neurons were
observed and counted on the computer monitor with a KS
100 imaging system (Carl Zeiss, Hallbergmoos, Ger-
many). After confirmation of layers in the spinal dorsal
horn in accordance with reports by Molander et al. [8],
images at 400× magnification were imported into the
computer to check for c-Fos-immunoreactive neurons.
From 30 sections per sample test rat, 5 sections were cho-
sen with the maximum number of c-Fos-immunoreactive
neurons for layers I–VI. The spinal dorsal horn was
divided into 3 groups: layers I–II; III–IV; and V–VI. The
mean number of c-Fos-immunoreactive neurons for lay-
ers I–II was set as a measured value for a test rat. Statistical
analysis was performed using a Bonferroni/Dunn test.
Values of p < 0.05 were considered statistically significant.
Results
Measurement of pain threshold
Pain threshold of normal paws (contralateral side) was
255.0 ± 17.0 g, compared to 136.0 ± 4.0 g for inflamed
paws 4.5 h after injection (0 h after treatment). Pain
threshold in the control group decreased to 90 ± 17 g,
while that in the other 4 groups was increased 3 h after
treatment (Fig. 3). In the loxoprofen-Na group, pain
threshold was significantly increased compared with the
control group (p < 0.05).
Amount of PGE2
Amount of PGE2 was 1.01 ± 0.25 ng in treatment-naïve
rats, and 8.97 ± 3.1 ng in the control group. Amounts of
PGE2 were 3.34 ± 1.53 ng in the loxoprofen-Na group,
10.49 ± 8.78 ng in the felbinac group, 1.16 ± 0.13 ng in
the indomethacin group and 4.72 ± 2.42 ng in the keto-
profen group. Significant differences in amounts of PGE2
were seen between control group and the loxoprofen-Na
and indomethacin groups (p < 0.05) (Fig. 4).
Expression of c-Fos
Immunoreactivity to c-Fos was observed in superficial
laminae of the dorsal horn in all groups (Fig. 5). Numbers
of c-Fos-immunoreactive cells in the 4 treatment groups
were decreased compared with the control group (Table
1). In particular, c-Fos-immunoreactivity was significantly
less in the loxoprofen-Na group than in the control group
(p < 0.05) (Table 1).
Discussion
NSAIDs are the most widely used drugs for reduction of
inflammation and pain in clinical situations [9]. How-
ever, side effects upon oral administration of NSAIDs
include gastrointestinal disturbance and hepatic dysfunc-
tion. Reducing these side effects while maintaining the
drug's therapeutic effects is important, as is exposing the
target region to the drugs for a suitable length of time. To
reduce side effects and enhance therapeutic effects, chang-
ing the route or method of administration is effective even
without changing the chemical structure. Drugs can be
given orally, intravenously, intrarectally or percutane-
ously. Blood concentrations of NSAIDs rise after oral
administration, and systemic side effects may result. In
contrast, percutaneous absorption only acts locally and is
expected to increase drug concentrations and produce
higher effects at the site of inflammation, thus reducing
side effects throughout the whole body. Percutaneously
delivered NSAIDs were thus developed to reduce inflam-
Pain threshold in inflamed paws (n = 6 per group) Figure 3
Pain threshold in inflamed paws (n = 6 per group). No 
difference was seen among groups at 4.5 h after injection of 
yeast suspension (0 h). Pain threshold increased 3 h after 
treatment in treated groups. In the loxoprofen-Na group, 
pain threshold significantly increased compared with the con-
trol group (*p < 0.05).
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mation and pain. Percutaneous absorption allows drugs
to permeate the skin and affect the local area [10]. How-
ever, this method is not used as main clinical treatment
due to the placebo effect. Depending on the substances
facilitating permeability of NSAIDs through the skin,
patients feel coldness or warmth on the skin and can also
notice various smells. These factors can act to create pla-
cebo effects, influencing assessment of the effect of plas-
ters that contain NSAIDs. The present experimental study
was performed to exclude such possible placebo effects.
Changes in the diameter of the paw in this acute inflam-
matory model have been reported in experimental studies
after oral administration of NSAIDs, but not following
percutaneous absorption [11]. However, no reports have
described analgesic effects after topical administration of
NSAIDs in an experimental study. In this study, percuta-
neous absorption of NSAIDs displayed analgesic effects
compared with the control group. Loxoprofen sodium
was particularly effective. Although inflammation had
already developed before treatment, percutaneously
absorbed NSAIDs were effective in increasing pain thresh-
olds locally. This result suggests that the local concentra-
tion of NSAIDs in inflamed tissue increases following
permeation through the skin and is sufficient to achieve
analgesic effects.
Analgesic effects of NSAIDs are associated with inhibition
of PG production. In particular, PGE2 and PGI2 increase
the effect of bradykinin, a pain-inducing substance. PGE2,
one of the principal inflammatory mediators, reportedly
contributes to the induction of peripheral hyperalgesia
and allodynia [1]. In the present study, yeast-induced
inflammation increased PGE2 content in the paw. This
increase of PGE2 may contribute to local inflammation
and decreased pain thresholds. The amount of PGE2
decreased after treatment, so percutaneous absorption of
NSAIDs may have inhibited PGE2 production to reduce
pain in the inflamed hind paw. Treatment was started just
after inducing inflammation, and the time interval
between treatment and PGE2 measurement was 30 min.
Percutaneously absorbed NSAIDs thus appear to work
quickly. PGE2 levels at later post-treatment time points
were not measured, which was a limitation to this study.
However, inhibition of PG biosynthesis is known to indi-
rectly inhibit bradykinin generation. Since increases in
pain threshold remained present 3 h after initiation of
treatment in this study, PGE2 biosynthesis was assumed to
be inhibited even after 30 min.
Expression of the c-Fos gene is an effective way to signal
sensory cells in a spinal cord and trigeminal nuclei excited
by noxious inputs. In particular, c-Fos-activated cells are
found in the ipsilateral superficial layer (I and II) in the
dorsal horn of the spinal cord 2 h after noxious input such
as mustard oil, formalin and carrageenin [2-4,12,13]. A
previous study identified c-fos mRNA in the spinal cord
after the formalin test, and expression of c-Fos peaked at
30 min in the superficial laminae of the dorsal horn (lam-
inae I–II) and at 1–3 h in the deep laminae (laminae
V–VI) [7]. Expression of c-Fos mRNA in those regions
appears to correspond to early- and late-phase responses
to the formalin test [14]. Some reports have evaluated
NSAID effects for oral and intravenous administration
using c-Fos expression in the spinal cord [9,14-21]. How-
ever, no previous studies have investigated the expression
of c-Fos after treatment by percutaneously absorbed
NSAIDs. In the present study, percutaneous local absorp-
Table 1: Number of c-Fos-immunoreactive cells in superficial laminae of the ipsilateral dorsal horn (n = 5 per group)
Control Loxoprofen-Na Felbinac Indomethacin Ketoprofen
Mean ± SEM 134.8 ± 4.5 113.7 ± 4.7 125.3 ± 5.4 127.5 ± 4 127.2 ± 3.5
p value vs. control 0.0008* 0.1268 0.2164 0.2227
The number of c-Fos-immunoreactive cells was decreased in the loxoprofen-Na group compared with the control group (* p < 0.05).
PGE2 in inflamed paws Figure 4
PGE2 in inflamed paws. In the control group, the amount 
of PGE2 increased 0.5 h after inducing inflammation. A signifi-
cant difference in the amount of PGE2 was identified between 
the control group and treatment-naïve animals (*p < 0.05). 
The amount of PGE2 in the groups treated with loxoprofen-
Na and indomethacin was decreased compared with the con-
trol group (*p < 0.05) (n = 5 for naïve group; n = 6 for treat-
ment groups).
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tion of NSAIDs into inflamed tissue inhibited expression
of c-Fos in the spinal cord compared with controls. Loxo-
profen-Na was especially effective in decreasing c-Fos
expression. These results suggest that loxoprofen-Na can
be effective in the early stage of inflammation induction
compared with other drugs. Treatment for >25 min prior
to induction of inflammation has been performed to eval-
uate expression of c-Fos [11,19-21]. In this study, treat-
ment was started just after inducing inflammation, and
only one treatment group could prevent c-Fos expression.
However, other time points and durations of effect were
not investigated and thus this may be limitations to this
study. In addition, dose and drug metabolism of NSAIDs
differ depending on whether treatment is oral or by percu-
taneous absorption, so the effect of percutaneously
absorbed NSAIDs cannot be directly compared with oral
NSAIDs. Nevertheless, NSAIDs administered systemically
affect not only inflamed tissues, but also tissues where
prostanoids play physiological roles. This means that oral
administration of NSAIDs carries risks of adverse effects
such as gastric ulcer and edema. In contrast, percutane-
ously absorbed NSAIDs affect only the local area, so the
risk and severity of adverse effects might be reduced com-
pared with oral NSAIDs.
We investigated the effect of percutaneously absorbed
NSAIDs by measuring pain threshold, amount of PGE2
and expression of c-Fos in the dorsal horn. No previous
reports have used these three categories to investigate the
effects of percutaneously absorbed NSAIDs. We found
that these effects are not placebo effects, and percutaneous
absorption of NSAIDs can be expected to be useful as a
main method of conservative treatment instead of oral
administration. In particular, percutaneous absorption of
NSAIDs is likely to be useful for patients with localized
disease or risk factors, and for elderly individuals with a
higher risk of side effects.
Conclusion
Percutaneously absorbed NSAIDs have analgesic effects,
inhibit expression of c-Fos in the dorsal horn, and reduce
PGE2 levels in inflamed tissues. This type of topical appli-
cation may be useful for acute inflammation and local-
ized pain.
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